Skip to content

Study · Animal study (in vivo) · dog and rat · 1986

8 results

Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration.

Ezan E, Drieu K, Chapelat M, Rougeot C, Dray F

Regulatory peptides1 Apr 1986Cited by 14 (Europe PMC)

PMID2940625 (opens in a new tab)DOI10.1016/0167-0115(86)90216-8 (opens in a new tab)PepBankPUB-02940625
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, triptorelin had a longer plasma half-life than native LHRH, with an elimination half-life above 80 minutes.

    In plain wordsIn dogs, triptorelin remained in plasma longer than native LHRH.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseElimination half-life
    Study

    dogn: not reported in source

    In vivo pharmacokinetics
    Comparator
    Native LHRH
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneous or intravenousAs given in this study (dog).

    Measurements

    Elimination half-life
    > 80 min
    subcutaneous or intravenous injection

    Source sentences

    Summary
    In both cases, the LHRH analog showed longer plasma half-life than native LHRH with an elimination half-life superior to 80 min.
    1 context sentence
    Summary · context
    The in vivo fate of the peptide was investigated in dogs after subcutaneous or intravenous injections.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, plasma triptorelin rose to 2.9-4.6 ng/ml the day after long-acting formulation administration.

    In plain wordsIn dogs, plasma triptorelin increased the day after a long-acting dose.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePlasma level next day
    Study

    dogn: not reported in source

    Long-acting formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Plasma concentration
    2.9 to 4.6 ng/ml
    day after administration

    Source sentences

    Summary
    Long-acting formulations were tested in dogs and rats: the day following administration, [D-Trp6]-LHRH plasma level rose to 2.9-4.6 ng/ml in dogs and 0.8-3.8 ng/ml in rats.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, plasma triptorelin rose to 0.8-3.8 ng/ml the day after long-acting formulation administration.

    In plain wordsIn rats, plasma triptorelin increased the day after a long-acting dose.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreasePlasma level next day
    Study

    ratn: not reported in source

    Long-acting formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Plasma concentration
    0.8 to 3.8 ng/ml
    day after administration

    Source sentences

    Summary
    Long-acting formulations were tested in dogs and rats: the day following administration, [D-Trp6]-LHRH plasma level rose to 2.9-4.6 ng/ml in dogs and 0.8-3.8 ng/ml in rats.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In dogs, plasma triptorelin plateaued at 0.3-0.8 ng/ml from day 4 to day 30.

    In plain wordsIn dogs, plasma triptorelin stayed within a plateau range from day 4 to day 30.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicablePlasma plateau
    Study

    dogn: not reported in source

    Long-acting formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Plasma concentration
    0.3 to 0.8 ng/ml
    days 4-30

    Source sentences

    Summary
    From day 4 to day 30, [D-Trp6]-LHRH plasma level followed a plateau with concentrations of 0.3-0.8 ng/ml in dogs and 0.2-0.4 ng/ml in rats.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, plasma triptorelin plateaued at 0.2-0.4 ng/ml from day 4 to day 30.

    In plain wordsIn rats, plasma triptorelin stayed within a plateau range from day 4 to day 30.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicablePlasma plateau
    Study

    ratn: not reported in source

    Long-acting formulation
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Plasma concentration
    0.2 to 0.4 ng/ml
    days 4-30

    Source sentences

    Summary
    From day 4 to day 30, [D-Trp6]-LHRH plasma level followed a plateau with concentrations of 0.3-0.8 ng/ml in dogs and 0.2-0.4 ng/ml in rats.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In dogs, triptorelin reduced plasma testosterone to castrate levels between day 4 and day 7.

    In plain wordsIn dogs, triptorelin reduced testosterone to castrate levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTestosterone
    Study

    dogn: not reported in source

    Long-acting formulation
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In parallel, testosterone plasma concentration was reduced to castrate level between day 4 and day 7 in dogs and was significantly lowered in rats.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats, long-acting triptorelin significantly lowered plasma testosterone.

    In plain wordsIn rats, long-acting triptorelin lowered testosterone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTestosterone
    Study

    ratn: not reported in source

    Long-acting formulation
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In parallel, testosterone plasma concentration was reduced to castrate level between day 4 and day 7 in dogs and was significantly lowered in rats.

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 08LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cell-free)Activity measurement

    In lab tests, the triptorelin radioimmunoassay detected a minimum concentration of 10 pg/ml in unextracted plasma.

    In plain wordsIn lab tests, the triptorelin assay detected concentrations as low as 10 pg/ml.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableAssay detection limit
    Study

    n: not reported in source

    Plasma radioimmunoassay
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Minimum detectable concentration
    10 pg/ml
    unextracted plasma

    Source sentences

    Summary
    This assay allowed measurement of the LHRH analog in unextracted plasma with a minimum detectable concentration of 10 pg/ml.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.